Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial

American Journal of Cardiology

Volumn 78, Issue 9, 1996, Pages 1011-1016

  Lees, Robert S ^a   Pitt, Bertram ^b   Chan, Raymond C ^b   Holmvang, Godtfred ^b   Dinsmore, Robert E ^b   Campbell, Lee W ^b   Haber, Harry E ^b   Klibaner, Michael I ^b   Cashin Hemphill, Linda ^b  

^a Boston Heart Foundation   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOQUINOLINE DERIVATIVE; LIPID; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DECISION TREE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DECISION TREES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOQUINOLINES; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SMOKING; TETRAHYDROISOQUINOLINES;

EID: 0030293448     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00526-7     Document Type: Article

References (30)

1. Yusuf S, Pepine C, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.
2. Pfeffer M, Braunwald E, Moye L, Basta L, Brown E, Cuddy T, Davis B, Geltman E, Goldman S, Flaker G, Klein M, Lamas G, Packer M, Rouleau J, Rutherford J Wertheimer J, Hawkins C, SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.
3. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
4. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard ACG. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drug Ther 1993;7:273-282.
5. Lees RS, Dinsmore RE. Can ACE inhibition alter the course of coronary heart disease? Rationale and protocol for QUIET. J Cardiovasc Pharmcol 1992;20(suppl B):S33-S35.
6. Leung WH, Saunders W, Alderman EL. A coronary artery quantitation and data management system for paired cine-angiograms. Cathet Cardiovasc Diagn 1991;24:121-134.
7. Selzer RH, Hagerty C, Azen SP, Siebes M, Lee P, Shircore A, Blankenhorn DH, and the Cholesterol Lowering Atherosclerosis Study Investigators and Staff. Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical trials. A sampling study. J Clin Invest 1989;83:520-526.
8. Principal Investigators of CASS and their associates (Killip T, editor, Fisher LD, Mock MB, associated eds). National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS). Circulation 1981;63(suppl I):I-1.
9. Blankenhorn D, Nessim S, Johnson R, Sanmarco M, Azen S, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
10. Mantel N, Haentszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
11. Breslow N, Day NE. Statistical Methods in Cancer Research, Vol 1: The Analysis of Case-Control Studies; Vol 2: The Design and Analysis of Cohort Studies. Lyon: IARC, 1980, 1987.
12. Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: Iowa State University Press, 1967.
13. Reiber JHC, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schwrbiers JCH, Boer AD, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cine-angiograms. Circulation 1985;71:280-288.
14. Williams G. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1525.
15. Campbell D. The site of angiotensin production. J Hypertens 1985;3:199-207.
16. Kuga T, Egashira K, Mohri M, Tsutsui H, Harasawa Y, Urabe Y, Ando S, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 1995;92:183-189.
17. Farhy R. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992;182:283-288.
18. Griendling K. Angiotensive II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
19. Daemen M, Lombardi D, Bosman F, Schwatz S. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
20. Katz A. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-747.
21. Naftilan A, Pratt R, Dzau V. Induction of platelet-derived growth-factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
22. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interation between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
23. Clozel M, Kuhn H, Hefti F, Baumgartner H. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991;18:132-141.
24. Chobanian A, Haudenschild C, Nickerson C, Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
25. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovas Pharmacol 1990;15:S65-S72.
26. Rolland P, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodaard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993;71:22E-27E.
27. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales M, Evans A, Arveileer D, Cambou J, Luc G, Rakotovao R, Ducimetiere P, Soubrier F, Alhenc-Gelas F. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90:669-676.
28. Katsuya T, Horiuchi M, Chen Y-D, Koike G, Pratt R, Dzau V, Reaven G. Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia. Arterioscler Thromb Vasc Biol 1995;15:779-782.
29. Blankenhorn D, Azen S, Kramsch D, Mack W, Cashin-Hemphill L, Hodis H, DeBoer L, Mahrer P, Masteller M, Vailas, L, Alaupovic P, Hirsch L and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Int Med 1993;119:969-976.
30. Mancini JGB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CS, Pitt B. Angiotensin converting enzyme inhibition, with quinapril, improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. J Am Coll Cardiol 1996;27:19A.